Past Performance: Past Performance is not an indicator of future results.
Bionano Genomics Inc. (BNGO) is a life-science instrumentation company focussed on the study of genetics for applications in the academic and medical fields. Headquartered in San Diego, California, Bionano's featured product is its proprietary Saphyr genome mapping system. Core business segments involve the production of Saphyr optical genome mapping instruments, nanochannel chips, prep kits and data solutions.[1]
Shares of BNGO stock are listed for trade on the NASDAQ exchange. As of March 2021, BNGO held a market capitalisation of US$1.65 billion, with more than 180 million shares outstanding.[2] Amid the initial stages of the COVID-19 pandemic, BNGO posted a trading range of US$0.25-US$15.69 from March 2020 to March 2021.[2]
There was a flurry of corporate activity and news during the week of August 8-12, with Disney, Dutch retailer Ahold Delhaize, EV start-up Rivian and other companies attracting our attention
The Walt Disney Company released strong quarterly results on Wednesday, with its streaming services reporting total subscribers that were higher than those of rival Netflix
The first week of August remained a busy one, as we had a large number of high profile corporations releasing their financial results, such as chip-maker AMD, British energy giant…
The last week of July was dominated by the Big Tech earnings, but the auto industry, plane makers and retailers were also in the spotlight
The earning season heated up this week (July 18-22), as Tesla, Netflix and Snap released their results, while more news stood out, such as Ford’s EV update and more
The king of the Electric Vehicle market reported overall solid results for Q2, but comparisons with the previous quarter are not flattering
| Retrieved 21 Mar 2021 https://bionanogenomics.com/products/ | |
| Retrieved 21 Mar 2021 https://www.cnbc.com/quotes/BNGO |
| Retrieved 21 Mar 2021 https://bionanogenomics.com/products/ | |
| Retrieved 21 Mar 2021 https://www.cnbc.com/quotes/BNGO |
When executing customers' trades, FXCM can be compensated in several ways, which include, but are not limited to: spreads, charging commissions at the open and close of a trade, and adding a mark-up to rollover, etc. Commission-based pricing is applicable to Active Trader account types.
Risk Warning: Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.
Exchange: ${getInstrumentData.exchange}
${getInstrumentData.bid} ${getInstrumentData.divCcy} ${getInstrumentData.priceChange} (${getInstrumentData.percentChange}%) ${getInstrumentData.priceChange} (${getInstrumentData.percentChange}%)
Any opinions, news, research, analyses, prices, other information, or links to third-party sites contained on this website are provided on an "as-is" basis, as general market commentary and do not constitute investment advice. The market commentary has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is therefore not subject to any prohibition on dealing ahead of dissemination. Although this commentary is not produced by an independent source, FXCM takes all sufficient steps to eliminate or prevent any conflicts of interests arising out of the production and dissemination of this communication. The employees of FXCM commit to acting in the clients' best interests and represent their views without misleading, deceiving, or otherwise impairing the clients' ability to make informed investment decisions. For more information about the FXCM's internal organizational and administrative arrangements for the prevention of conflicts, please refer to the Firms' Managing Conflicts Policy. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed here.